| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -37,025 | -24,317 |
| Depreciation | 333 | 205 |
| Gain from sale of property, plant and equipment | 15 | - |
| Changes in fair value of marketable securities, net of interest received | 178 | 155 |
| Change in liability for employees rights upon retirement | -371 | -277 |
| Other financial income | 113 | 58 |
| Change in operating right of use asset and operating leasing liability | -480 | -377 |
| Share-based compensation expenses | 9,484 | 5,940 |
| Loss (gain) on amounts funded in respect of employee rights upon retirement, net | 121 | 95 |
| Decrease (increase) in prepaid expenses | -115 | -113 |
| Decrease (increase) in trade receivables | 389 | 20 |
| Decrease (increase) in other receivables | -207 | -186 |
| Increase in inventory | 1,037 | 484 |
| Increase in trade payables | 499 | 264 |
| Increase in other payables | 1,631 | 642 |
| Net cash used in operating activities | -25,758 | -17,125 |
| Purchase of property, plant and equipment | 1,264 | 935 |
| Proceeds from sale of property, plant and equipment | 15 | - |
| Investments in marketable securities | 11,749 | 11,749 |
| Proceeds from matured marketable securities | 27,648 | 19,760 |
| Amounts funded in respect of employee rights upon retirement | 75 | 52 |
| Net cash provided by investing activities | 14,575 | 7,024 |
| Proceeds from exercise of warrants, net of 1,000 issuance costs | 16,855 | 1,947 |
| Proceeds from issuance of shares and pre-funded warrants, net of 3,148 and 1 issuance costs, respectively | 38,714 | 696 |
| Net cash provided by financing activities | 55,569 | 2,643 |
| Effect of exchange rate changes on cash and cash equivalents | 101 | 51 |
| Increase in cash and cash equivalents | 44,487 | -7,407 |
| Cash and cash equivalents at beginning of period | 18,916 | - |
| Cash and cash equivalents at end of period | 63,403 | - |
InspireMD, Inc. (NSPR)
InspireMD, Inc. (NSPR)